Clinical Colorectal Cancer

Journal Information
ISSN / EISSN : 1533-0028 / 1938-0674
Current Publisher: Elsevier BV (10.1016)
Former Publisher: Elsevier BV (10.3816)
Total articles ≅ 1,331
Current Coverage
SCOPUS
PUBMED
MEDLINE
MEDICUS
SCIE
Archived in
SHERPA/ROMEO
Filter:

Latest articles in this journal

, , Jeffrey R. Olsen, Matthew G. Mutch, , , , Matthew L. Silviera, Benjamin R. Tan, Andrea Wang-Gillam, et al.
Published: 1 April 2021
Clinical Colorectal Cancer; doi:10.1016/j.clcc.2021.03.003

The publisher has not yet granted permission to display this abstract.
, J.R. Beecroft, , E. David, M. Kalyvas, E. Kennedy, G. Sapisochin, R. Wong, K. Zbuk
Published: 1 March 2021
Clinical Colorectal Cancer, Volume 20, pp 20-28; doi:10.1016/j.clcc.2020.09.008

The publisher has not yet granted permission to display this abstract.
Femke C.R. Staal, Denise J. van der Reijd, Marjaneh Taghavi, Doenja M.J. Lambregts, Regina G.H. Beets-Tan,
Published: 1 March 2021
Clinical Colorectal Cancer, Volume 20, pp 52-71; doi:10.1016/j.clcc.2020.11.001

The publisher has not yet granted permission to display this abstract.
, Elizabeth Sakach, Urvi Patel, Marley Watson, Kevin Hall, Amber Draper, Christine Davis, Subir Goyal, , Mehmet Akce, et al.
Published: 1 March 2021
Clinical Colorectal Cancer; doi:10.1016/j.clcc.2020.12.002

The publisher has not yet granted permission to display this abstract.
Manish Parihar, Sherry G. Dodds, Gene Hubbard, Martin A. Javors, Randy Strong, ,
Published: 1 March 2021
Clinical Colorectal Cancer, Volume 20; doi:10.1016/j.clcc.2020.08.006

Abstract:
S Micro Rapamycin extends life and health span in wild type mice suggesting prevention of cancer. We show rapamycin extends survival in colon cancer prone mice and that crypt cells are primary targets of mTOR inhibition that mediate tumor prevention or delay. Structured We previously showed that lifelong rapamycin treatment of short lived Apc Min/+ mice, a model for familial adenomatous polyposis (FAP), resulted in a normal lifespan. Apc Min/+ mice develop colon polyps with a low frequency but can be converted to a colon cancer model by dextran sodium sulfate (DSS) treatments (Apc Min/+-DSS model). We asked, what effect would pretreatment of Apc Min/+ mice with chronic rapamycin prior to DSS exposure have on survival and colonic neoplasia? Forty-two ppm eRapa diet exacerbated the temporary weight loss associated with DSS treatment in both sexes. However, our survival studies showed that chronic rapamycin treatment significantly extended lifespan of Apc Min/+-DSS mice (both sexes) by reductions in colon neoplasia and prevention of anemia. Rapamycin also had prophylactic effects on colon neoplasia induced by azoxymethane (AOM) and DSS in C57BL/6 males and females. Immunoblot assays showed the expected inhibition of mTORC1 and effectors (S6K→rpS6 and S6K→eEF2K→eEF2) in colon by lifelong rapamycin treatments. To address the question of cell types affected by chronic enteric rapamycin treatment, immunohistochemistry analyses demonstrated that crypt cells had a prominent reduction in rpS6 phosphorylation and increase in eEF2 phosphorylation relative controls. These data indicate that enteric rapamycin prevents or delays colon neoplasia in Apc Min/++DSS mice through inhibition of mTORC1 in the crypt cells.
Published: 1 March 2021
Clinical Colorectal Cancer, Volume 20; doi:10.1016/j.clcc.2020.07.007

The publisher has not yet granted permission to display this abstract.
, Mohammad Afshar, Coralie Williams, Thomas Turcat, David Parker, Eva Gordon, Jessica Zambelli, Amber MacDonald, Collen Suh, Sheley Baylon, et al.
Published: 1 March 2021
Clinical Colorectal Cancer, Volume 20, pp 96-99; doi:10.1016/j.clcc.2020.10.003

Abstract:
The practice of precision medicine is defined by the discovery of actionable insights emanating from molecular diagnosis. While serial DNA sequencing may reveal mutations that supervene in causing treatment resistance, the transcriptome has been little explored in the clinic. We report here a case report of a patient with metastatic colon cancer who developed resistance to HER2-targeted therapies with mechanisms that could not be identified by genomic analyses, but which were uncovered by RNA-seq. Serial evaluation of gene expression appears to be a valuable tool for diagnosing a specific mechanisms of treatment resistance, i.e. the resistome, arising from altered gene expression rather than from genomic abnormalities.
, Cristina Lucidi, Giovanni Bruno, Daniele Lisi, Lucia Miglioresi, Marco Emilio Bazuro
Published: 1 March 2021
Clinical Colorectal Cancer, Volume 20; doi:10.1016/j.clcc.2020.07.006

Abstract:
Introduction One of the main clusters of coronavirus disease-2019 (COVID-19) has been identified in Italy. Following European and local guidelines, Italian endoscopy units modulated their activity. We aimed at analyzing the need and safety to continue selective colorectal cancer screening (CRCS) colonoscopies during the COVID-19 pandemic. Patients and Methods We carried out a retrospective controlled cohort study in our "COVID-free" hospital to compare data of the CRCS colonoscopies of the lockdown period (March 9 to May 4, 2020) with those of the same period of 2019 (control group). A pre/post endoscopic sanitary surveillance for COVID-19 infection was organized for patients and sanitary staff. Results In the lockdown group, 60 of 137 invited patients underwent endoscopy, whereas in the control group, 238 CRCS colonoscopies (3.9-fold) were performed. In the lower number of examinations during the lockdown, we found more colorectal cancers (5 cases; 8% vs. 3 cases; 1%; P = .002). The "high-risk" adenomas detection rate was also significantly higher in the "lockdown group" than in controls (47% vs. 25%; P = .001). A multiple regression analysis selected relevant symptoms (hazard ratio [HR], 3.1), familiarity (HR, 1.99), and lockdown period (HR, 2.2) as independent predictors of high-risk lesions (high-risk adenomas and colorectal cancer). No COVID-19 infections were reported among staff and patients. Conclusions The overall adherence to CRCS decreased during the pandemic, but the continuation of CRCS colonoscopies was efficacious and safe.
, Azim Jalali, Stephen Begbie, Christine Semira, Suzanne Kosmider, Sumitra Ananda, Rachel Wong, Margaret Lee, Jeremy Shapiro, Matthew Burge, et al.
Published: 1 March 2021
Clinical Colorectal Cancer, Volume 20; doi:10.1016/j.clcc.2020.08.002

The publisher has not yet granted permission to display this abstract.
Back to Top Top